IM Cannabis to Report Third Quarter 2022 Financial Results on Monday, November 14 at 9:00am ET
TORONTO and GLIL YAM, Israel, Nov. 1, 2022 /PRNewswire/ -- IM Cannabis Corp. (the "Company" or "IM Cannabis") (CSE: IMCC) (NASDAQ: IMCC), a leading medical and adult-use recreational cannabis company with operations in Israel, Canada, and Germany, will report operational and financial results for the third quarter ended September 30, 2022, on Monday, November 14, 2022 before market opens.
The Company will host a zoom web conference on the same day at 9:00a.m. ET to discuss the results, followed by a question-and-answer session for the investment community. Investors are invited to register by clicking here. All relevant information will be sent upon registration.
If you are unable to join us live, a recording of the call will be available on our website at https://investors.imcannabis.com/ within 24 hours after the call.
About IM Cannabis Corp.
IM Cannabis (NASDAQ: IMCC) (CSE: IMCC) is a leading international cannabis company providing premium products to medical patients and adult-use recreational consumers. IM Cannabis is one of the very few companies with operations in Israel, Germany, and Canada, the three largest federally legal markets. The ecosystem created through its international operations leverages IMC's unique data-driven perspective and product supply chain globally. With its commitment to responsible growth and financial prudence, and the ability to operate within the strictest regulatory environments, IMC has quickly become one of the leading cultivators and distributors of high-quality cannabis globally.
The IM Cannabis ecosystem operates in Israel through its commercial relationship with Focus Medical, which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. IMC also operates medical cannabis retail pharmacies, online platforms, distribution centers and logistical hubs in Israel that enable the safe delivery and quality control of IM Cannabis products throughout the entire value chain. In Germany, the IM Cannabis ecosystem operates through Adjupharm GmbH, where it also distributes cannabis to pharmacies for medical cannabis patients. In Canada, IM Cannabis operates through Trichome Financial Corp. and its subsidiaries Trichome JWC Acquisition Corp. and MYM Nutraceuticals Inc., where it cultivates and processes cannabis for the adult-use market from its facilities in Ontario and Nova Scotia under the WAGNERS and Highland Grow brands. For more information, please visit www.imcannabis.com.
Maya Lustig, Director Investor & Public Relations
Oren Shuster, CEO
IM Cannabis Corp.
SOURCE IM Cannabis Corp
Released November 1, 2022